^
Contact us to learn more about
our Premium Content: News alerts, weekly reports and conference plannersDRUG:
Dasynoc (dasatinib amorphous)
i
Other names: HyNap-Dasa, XS004
Contact us to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Company:
Handa Pharma, Xspray Pharma
Drug class:
Bcr-abl inhibitor
Related drugs:
over2years
Despite warnings, co-medication with proton pump inhibitors and dasatinib is common in chronic myeloid leukemia, but XS004, a novel oral dasatinib formulation, provides reduced pH-dependence, minimizing undesirable drug-drug interactions. (PubMed, Eur J Haematol)
In conclusion, despite warnings, PPI co-medication is common among dasatinib-treated CML patients in a real-world setting. The new XS004 ASD formulation of dasatinib provided, in contrast to original crystalline dasatinib, superior pH independence with stable bioavailability, thereby minimizing drug-drug interactions. This may improve the long-term efficacy and tolerability of dasatinib in CML.
Journal
|
Dasynoc (dasatinib amorphous) • omeprazole
Share via
